ACADIA PHARMACEUTICALS INC. Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five
ACADIA PHARMACEUTICALS INC. (ACAD) had Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five of 37.00% as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity
us-gaap:DebtSecuritiesAvailableForSaleMaturityAfterOneThroughFiveYearsWeightedAverageYield · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five 37.00%.
- 2026-03-31: Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five 41.00%.
- 2025-12-31: Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five 49.00%.
- 2025-09-30: Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five 49.00%.
| Period end | Debt Securities, Available-for-Sale, Weighted Average Yield, Maturity, after Year One Through Five |
|---|---|
| 2026-06-30 | 37.00% 10-Q · filed 2026-08-05 |
| 2026-03-31 | 41.00% 10-Q · filed 2026-05-07 |
| 2025-12-31 | 49.00% 10-Q · filed 2026-08-05 |
| 2025-09-30 | 49.00% 10-Q · filed 2025-11-06 |
| 2025-06-30 | 43.00% 10-Q · filed 2025-08-07 |
| 2025-03-31 | 35.00% 10-Q · filed 2025-05-08 |
| 2024-12-31 | 21.00% 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |